Results 161 to 170 of about 9,514 (200)
Some of the next articles are maybe not open access.
Leveraging Hypomethylating Agents for Better MDS Therapy
Current Hematologic Malignancy Reports, 2018Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy.
Terrence J, Bradley +2 more
openaire +2 more sources
Treatment with Hypomethylating Agents (HMA)
2018In 1993 Silverman and coworkers [1] reported on a phase 2 trial on 43 patients with higher-risk MDS (medullary blast count >10%) using 75 mg/m2 5-Azacytidine (5-Aza) for 7 days every 28 days for 6 cycles. Forty-nine percent of the patients responded, with 12% CR (CR and PR 37%, and 5% improved hematologically without achieving CR or PR), and 51% were ...
Ulrich Germing, Pierre Fenaux
openaire +1 more source
The use of hypomethylating agents in the treatment of hematologic malignancies
Leukemia & Lymphoma, 2007Epigenetic alterations, such as DNA methylation and histone modifications, are abnormal in cancer cells, and the use of the hypomethylating agents 5-azacitidine and decitabine are important additions to our arsenal of active cancer drugs, especially for the treatment of the myelodysplastic syndromes and acute myeloid leukemia.
Jane E, Kihslinger, Lucy A, Godley
openaire +2 more sources
Hypomethylating agents for patients with myelodysplastic syndrome
Cochrane Database of Systematic Reviews, 2011Reason for Withdrawal Authors have made no progress with this protocol in two years. New authors are being sought to take over this protocol. To view the published versions of this article, please click the 'Other versions' tab.
Kathrin Bauer +5 more
openaire +1 more source
Blood
Introduction The Charlson Comorbidity Index (CCI) is a predictive multivariate co-morbidity index shown to predict mortality in patients with acute myeloid leukemia (AML). In our previous work, we demonstrated that a CCI of > 6 was independently predictive of prognosis when treated with a ...
Graeme F Murray +4 more
openaire +1 more source
Introduction The Charlson Comorbidity Index (CCI) is a predictive multivariate co-morbidity index shown to predict mortality in patients with acute myeloid leukemia (AML). In our previous work, we demonstrated that a CCI of > 6 was independently predictive of prognosis when treated with a ...
Graeme F Murray +4 more
openaire +1 more source
The euphoria of hypomethylating agents in MDS and AML: Is it justified?
Best Practice & Research Clinical Haematology, 2013While it is logical to use hypomethylating agents to treat patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), trial results with azacitidine and decitabine have been inconsistent. Azacitidine confers a survival benefit in higher-risk MDS patients, while decitabine does not.
openaire +2 more sources
Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia
Current Cancer Drug Targets, 2011Epigenetic changes play an important role in cancer pathogenesis. Hypermethylation of DNA generally results in decreased expression of tumor suppressor genes and defective cell cycle control. This is a hallmark of myelodysplastic syndromes (MDS) and acute myeloid leukemia.
Anna, Szmigielska-Kapłon +1 more
openaire +2 more sources
Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes
Leukemia Research, 2012We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020).
Virginia M, Klimek +6 more
openaire +2 more sources
Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways
Current Cancer Drug Targets, 2010DNA methylation and histone acetylation are two most studied epigenetic markers. Aberrant methylation of gene promoter regions and histone tail lysine residue modification through acetylation and methylation play a key role in malignant disorders. Two DNA methyltransferase inhibitors, azacitidine and decitabine, have been licensed for clinical therapy ...
S, Cang, Q, Lu, Y, Ma, D, Liu
openaire +2 more sources
Use of hypomethylating agents in myelodysplastic syndromes.
Clinical advances in hematology & oncology : H&O, 2007Aberrant DNA methylation is one of the molecular hallmarks of cancer and leukemia. By repressing gene expression, it is considered a functional equivalent to the physical inactivation of tumor suppressor genes by deletions or mutations. To clinically exploit this process, compounds with DNA hypomethylating properties have been evaluated both in the ...
Ehab, Atallah, Guillermo, Garcia-Manero
openaire +1 more source